What's Happening?
CROSSJECT, a specialty pharmaceutical company, has published its financial results for 2025, highlighting significant progress in its operational, industrial, and financial trajectory. The company, known for its ZENEO® needle-free auto-injector technology,
is advancing the development and registration of ZEPIZURE®, an injectable for managing epileptic seizures. In 2025, CROSSJECT reported a 12.25% increase in operating revenue, reaching €14.9 million, and improved its net loss to €-10.4 million from €-12.8 million in 2024. The company also secured additional funding from BARDA, bringing total support to $43.3 million, and continued to develop its ZENEO® platform for intramuscular administration.
Why It's Important?
CROSSJECT's financial and operational improvements reflect its strategic focus on developing emergency medical solutions, which are critical in healthcare. The company's advancements in needle-free technology and its collaboration with BARDA underscore the importance of innovation in addressing urgent medical needs. The financial results indicate a strengthening position in the pharmaceutical industry, with potential for significant market impact as CROSSJECT prepares for regulatory submissions and commercialization. The company's progress may attract further investment and partnerships, enhancing its ability to deliver life-saving treatments.
What's Next?
CROSSJECT plans to continue its regulatory and operational preparations, aiming to submit an Emergency Use Authorization (EUA) application for ZEPIZURE® as soon as possible. The company is also preparing for direct commercialization in the United States, with plans to start ZEPIZURE® sales in 2027. As CROSSJECT advances its product pipeline, including ZENEO® Hydrocortisone and ZENEO® Adrenaline, it will explore various financing options to support its growth. The company's focus on regulatory milestones and market entry strategies will be crucial in achieving its commercial objectives.
